Skip to content
DataLookout
Menu

NCT07899905

A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24.
Timeframe: Baseline and Week 24
Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 37 weeks.
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 21 weeks.

Secondary (3)

Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24
Percentage of Participants with Improvement in World Health Organization (WHO) Functional Class (FC) at Week 24
Change from Baseline in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) at Week 24

Arms and interventions

SotaterceptExperimental

Sotatercept will be administered subcutaneous (SC) starting at a dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 3 weeks (Q3W) plus background Pulmonary Arterial Hypertension (PAH) therapy.

Biologicals: Sotatercept